SFRP4 and metastatic neoplasm: Although SFRP4 has not directly been shown to induce lytic bone metastasis like Dkk-1, it has been shown to inhibit osteoblast function in the same manner, so it can be speculated that SFRP4 can cause prostate cancer progression to metastatic disease through an increased ability to create bone lesions.